MorphoSys AG - Product Pipeline Review - Q2 2011

Global Markets Direct, July 2011, Pages: 68

MorphoSys AG – Product Pipeline Review – Q2 2011

Summary

Global Market Direct’s pharmaceuticals report, “MorphoSys AG - Product Pipeline Review - Q2 2011” provides data on the MorphoSys AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, MorphoSys AG’s corporate website, SEC filings, investor presentations and featured press releases, both from MorphoSys AG and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- MorphoSys AG - Brief MorphoSys AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of MorphoSys AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of MorphoSys AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the MorphoSys AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate MorphoSys AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of MorphoSys AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the MorphoSys AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with MorphoSys AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of MorphoSys AG and identify potential opportunities in those areas.

List of Tables
List of Figures
MorphoSys AG Snapshot
MorphoSys AG Overview
Key Information
Key Facts
MorphoSys AG – Research and Development Overview
Key Therapeutic Areas
MorphoSys AG – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
MorphoSys AG – Pipeline Products Glance
MorphoSys AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
MorphoSys AG–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
MorphoSys AG – Drug Profiles
MOR103
Product Description
Mechanism of Action
R&D Progress
MOR208
Product Description
Mechanism of Action
R&D Progress
MOR102
Product Description
Mechanism of Action
R&D Progress
MOR202
Product Description
Mechanism of Action
R&D Progress
MOR205
Product Description
Mechanism of Action
R&D Progress
MOR206
Product Description
Mechanism of Action
R&D Progress
MorphoSys AG – Pipeline Analysis
MorphoSys AG – Pipeline Products by Therapeutic Class
MorphoSys AG - Pipeline Products By Target
MorphoSys AG – Pipeline Products by Route of Administration
MorphoSys AG – Pipeline Products by Molecule Type
MorphoSys AG – Recent Pipeline Updates
MorphoSys AG - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
MOR203
MOR101
MOR102
MorphoSys AG – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
MorphoSys AG, Deals Volume Summary, 2004 to YTD 2011
MorphoSys AG, Deals Summary By Region, 2004 to YTD 2011
MorphoSys AG, Deals Summary, 2004 to YTD 2011
MorphoSys AG Detailed Deal Summary
Acquisition
MorphoSys Acquires AbD Serotec
Debt Offering
MorphoSys Completes Private Placement Of $11 Million
MorphoSys Expands Cooperation Agreement With Wacker Chemie
MorphoSys Enters Into Co-Development Agreement With DAIICHI SANKYO
AbD Serotec Enters Into Research Collaboration With Foundation for Innovative New Diagnostics
MorphoSys Enters Into Co-development Agreement With Galapagos
Sigma-Aldrich Enters Into An Agreement With MorphoSys
Novartis Expands Collaboration Agreement With MorphoSys
Genesis Research Enters Into Research Agreement With MorphoSys
MorphoSys Expands Co-Development Agreement With Pfizer
Boehringer Ingelheim Expands Research Agreement With MorphoSys
MorphoSys Expands Collaboration With Centocor Ortho Biotech
Boehringer Ingelheim Enters Into An Agreement With MorphoSys
MorphoSys Enters Into Strategic Collaboration With Novartis
Licensing Agreements
MorphoSys Enters Into Licensing Agreement With Shionogi
Schering-Plough Extends Its Licensing Agreement With MorphoSys
Shionogi & Co. Extends Licensing Agreement With MorphoSys
Daiichi Sankyo Expands Licensing Agreement With MorphoSys
MorphoSys Extends Licensing Agreement With Crucell And DSM Biologics
Astellas Pharma Extends Collaboration With MorphoSys
Dyax Enters Into Licensing Agreement With MorphoSys
MorphoSys Enters Into Licensing Agreement With Astellas Pharma
MorphoSys Enters Into Licensing Agreement With Daiichi Sankyo
MorphoSys Enters Into Licensing Agreement With Merck
MorphoSys Enters Into Licensing Agreement With Eli Lilly
MorphoSys Enters Into Licensing Agreement With Shionogi For HuCAL GOLD
ImmunoGen Enters Into Licensing Agreement With MorphoSys
MorphoSys Expands Licensing Agreement With Bristol-Myers Squibb
Crucell And DSM Biologics Enter Into Licensing Agreement With MorphoSys
MorphoSys Extends Licensing Agreement With Centocor
MorphoSys Enters Into Licensing Agreement With Centocor
GPC Biotech Extends License Agreement With MorphoSys
MorphoSys Enters Into Licensing Agreement With Bayer HealthCare
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
MorphoSys AG – Pipeline by Therapy Area and Indication, 2011
MorphoSys AG – Pipeline by Stage of Development, 2011
MorphoSys AG – Monotherapy Products in Pipeline, 2011
MorphoSys AG - Phase II, 2011
MorphoSys AG - Phase I, 2011
MorphoSys AG - Pipeline By Therapeutic Class, 2011
MorphoSys AG - Pipeline By Target, 2011
MorphoSys AG – Pipeline By Route of Administration, 2011
MorphoSys AG – Pipeline By Molecule Type, 2011
MorphoSys AG – Recent Pipeline Updates, 2011
MorphoSys AG - Discontinued Pipeline Products, 2010
MorphoSys AG, Subsidiaries
MorphoSys AG, Deals Summary, 2004 to YTD 2011
MorphoSys AG, Deals Summary by Region, 2004 to YTD 2011
MorphoSys AG, Deals Summary, 2004 to YTD 2011

List of Figures
MorphoSys AG – Pipeline by Therapy Area and Indication, 2011
MorphoSys AG – Pipeline by Stage of Development, 2011
MorphoSys AG – Monotherapy Products in Pipeline, 2011
MorphoSys AG – Pipeline By Therapeutic Class, 2011
MorphoSys AG - Pipeline By Target, 2011
MorphoSys AG – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Wincor Nixdorf AG
• Bechtle AG
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• SAP AG,(SAP) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• Siemens AG,(SI) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• United Internet AG,(UDIRF) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• Software AG
• Scientific Games Corporation - Company Analysis